Covid-19 vaccine: Bharat Biotech to conduct Phase-3 trials in 26,000 volunteers - Times of India
HYDERABAD: Bharat Biotech, which is into developing Covaxin, a vaccine candidate for Covid-19, on Friday said it has successfully completed interim analysis of Phase I and II trials and is initiating Phase-III trials in 26,000 participants.
“After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of Covaxin, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India,” the vaccine maker said in a communication.
Covaxin is being developed byBharatBiotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).
The city-based vaccine maker had on October 2 sought the Drug Controller General of India (DCGI)’s permission to conduct Phase 3 randomised double-blind placebo-controlled multi centre trial of its Covid-19 vaccine, sources said.
In July, the DCGI had given permission to Bharat Biotech to conduct Phase 1 and 2 clinical trials of its Covid-19 vaccine.
“After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of Covaxin, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India,” the vaccine maker said in a communication.
Covaxin is being developed byBharatBiotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).
The city-based vaccine maker had on October 2 sought the Drug Controller General of India (DCGI)’s permission to conduct Phase 3 randomised double-blind placebo-controlled multi centre trial of its Covid-19 vaccine, sources said.
In July, the DCGI had given permission to Bharat Biotech to conduct Phase 1 and 2 clinical trials of its Covid-19 vaccine.
For the latest news and updates, follow us on Google News. Also, if you like our efforts, consider sharing this story with your friends, this will encourage us to bring more exciting updates for you.
